Feasibility and long-term outcomes of hepatic vein recanalization in Budd-Chiari syndrome through intrahepatic collateral pathways.

IF 4.6 Q2 MATERIALS SCIENCE, BIOMATERIALS
ACS Applied Bio Materials Pub Date : 2024-10-01 Epub Date: 2024-07-15 DOI:10.1097/MEG.0000000000002822
Hongru Ma, Yabo Gou, Chao Wang, Jinchang Xiao, Bin Shen, Hongtao Liu, Qianxin Huang, Hao Xu, Maoheng Zu, Qingqiao Zhang
{"title":"Feasibility and long-term outcomes of hepatic vein recanalization in Budd-Chiari syndrome through intrahepatic collateral pathways.","authors":"Hongru Ma, Yabo Gou, Chao Wang, Jinchang Xiao, Bin Shen, Hongtao Liu, Qianxin Huang, Hao Xu, Maoheng Zu, Qingqiao Zhang","doi":"10.1097/MEG.0000000000002822","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and aims: </strong>To investigate the feasibility and long-term outcomes of hepatic vein (HV) recanalization using intrahepatic collateral pathways in patients with Budd-Chiari syndrome (BCS) with HV obstruction.</p><p><strong>Methods: </strong>Clinical data of 29 BCS patients with HV obstruction and intrahepatic collateral pathways were reviewed. All patients underwent HV recanalization through the intrahepatic collaterals. Follow-up was performed at 1, 3, 6, and 12 months after treatment and annually thereafter. Cumulative patency and survival rates were assessed using Kaplan-Meier curves. The independent predictors of patency were determined using a Cox regression model.</p><p><strong>Results: </strong>HV recanalization was successful in 28 of the 29 patients (96.6%), with no complications. Of the 28 cases, simultaneous recanalization of the accessory HV and right HV was achieved in 11 patients, accessory HV and middle HV in six, accessory HV and left HV in three, right HV and middle HV in five, and left HV and middle HV in three. Twenty-eight patients were followed from 4 to 87 (mean, 53.6 ± 26.7) months after treatment, and six patients developed reocclusion. The overall cumulative 1-, 3-, 5-, and 7-year primary HV patency rates were 96.3, 82.9, 74.6, and 59.7%, respectively. The cumulative 1-, 3-, 5-, and 7-year survival rates were 100, 95.8, 95.8, and 86.3%, respectively.</p><p><strong>Conclusion: </strong>Interventional treatment of HV obstruction in BCS patients through intrahepatic collateral approaches is well tolerated and feasible and can result in excellent long-term patency and survival rates.</p>","PeriodicalId":2,"journal":{"name":"ACS Applied Bio Materials","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Applied Bio Materials","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MEG.0000000000002822","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/15 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MATERIALS SCIENCE, BIOMATERIALS","Score":null,"Total":0}
引用次数: 0

Abstract

Background and aims: To investigate the feasibility and long-term outcomes of hepatic vein (HV) recanalization using intrahepatic collateral pathways in patients with Budd-Chiari syndrome (BCS) with HV obstruction.

Methods: Clinical data of 29 BCS patients with HV obstruction and intrahepatic collateral pathways were reviewed. All patients underwent HV recanalization through the intrahepatic collaterals. Follow-up was performed at 1, 3, 6, and 12 months after treatment and annually thereafter. Cumulative patency and survival rates were assessed using Kaplan-Meier curves. The independent predictors of patency were determined using a Cox regression model.

Results: HV recanalization was successful in 28 of the 29 patients (96.6%), with no complications. Of the 28 cases, simultaneous recanalization of the accessory HV and right HV was achieved in 11 patients, accessory HV and middle HV in six, accessory HV and left HV in three, right HV and middle HV in five, and left HV and middle HV in three. Twenty-eight patients were followed from 4 to 87 (mean, 53.6 ± 26.7) months after treatment, and six patients developed reocclusion. The overall cumulative 1-, 3-, 5-, and 7-year primary HV patency rates were 96.3, 82.9, 74.6, and 59.7%, respectively. The cumulative 1-, 3-, 5-, and 7-year survival rates were 100, 95.8, 95.8, and 86.3%, respectively.

Conclusion: Interventional treatment of HV obstruction in BCS patients through intrahepatic collateral approaches is well tolerated and feasible and can result in excellent long-term patency and survival rates.

通过肝内侧支途径对布德-恰里综合征的肝静脉进行再通畅的可行性和长期疗效。
背景和目的研究在伴有肝静脉(HV)阻塞的巴德-恰里综合征(BCS)患者中使用肝内侧瓣途径进行肝静脉(HV)再通的可行性和长期疗效:方法: 回顾性分析了 29 例伴有 HV 梗阻和肝内侧支通路的 BCS 患者的临床数据。所有患者都通过肝内侧支接受了 HV 再通路手术。在治疗后的 1、3、6 和 12 个月进行随访,此后每年进行一次随访。采用 Kaplan-Meier 曲线评估累积通畅率和存活率。采用 Cox 回归模型确定了通畅率的独立预测因素:结果:29 例患者中有 28 例(96.6%)成功进行了 HV 再封堵,无并发症发生。在这 28 例患者中,11 例实现了附属 HV 和右侧 HV 的同时再通畅,6 例实现了附属 HV 和中间 HV 的同时再通畅,3 例实现了附属 HV 和左侧 HV 的同时再通畅,5 例实现了右侧 HV 和中间 HV 的同时再通畅,3 例实现了左侧 HV 和中间 HV 的同时再通畅。治疗后对 28 名患者进行了 4 至 87 个月(平均 53.6 ± 26.7)的随访,其中 6 名患者出现再闭塞。1年、3年、5年和7年的原发性HV通畅率分别为96.3%、82.9%、74.6%和59.7%。1年、3年、5年和7年累积存活率分别为100%、95.8%、95.8%和86.3%:结论:通过肝内侧支途径对 BCS 患者的 HV 梗阻进行介入治疗具有良好的耐受性和可行性,可获得极佳的长期通畅率和存活率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
ACS Applied Bio Materials
ACS Applied Bio Materials Chemistry-Chemistry (all)
CiteScore
9.40
自引率
2.10%
发文量
464
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信